Business Wire

CA-ESRI

20.4.2022 14:02:25 CEST | Business Wire | Press release

Share
Esri Brings Powerful Mapping Technology to Everyone with New Storytelling Tool

Capturing and sharing life's experiences today often requires multiple platforms and tools, which can result in disjointed storytelling. To serve creators' needs to control their dynamic, interactive narratives in one place, Esri , the global leader in location intelligence, today released StoryMaps, a powerful, personal storytelling tool. The product extends Esri's creative capabilities to anyone who wants to tell their story and share it.

Using Esri's mapping technology, this new software brings the geographic approach to any content that creators are passionate about. From documenting their ancestral journey to capturing aspects of daily life or planning a first big post-pandemic trip, StoryMaps helps capture life's moments in a way worthy of those experiences.

"At Esri, we understand that sharing stories is a part of life, that everyone is a storyteller," said Jack Dangermond, Esri founder and president. "Every moment and memory we treasure is connected to a specific location, which is why we're making it easier to transport people anywhere in the world through richer storytelling."

Esri allows authors to control their narratives with built-in privacy to protect data and automatic content ownership and create them in versatile ways that reflect the experiences themselves. People can creatively combine text with multimedia like images, videos, audio, and links to easily share their personal experiences, hobbies, family history, ancestry, portfolios, travels, and more.

The National Geographic Society (NGS)—which for more than 130 years has been illuminating and protecting the world through science, exploration, education, and storytelling—is partnering with Esri to bring StoryMaps to its members.

"The National Geographic Society has a long legacy of storytelling, and it remains fundamental to our mission work today as we further our understanding of our planet and each other," said Jill Tiefenthaler, National Geographic Society chief executive officer. "Our partnership with Esri enriches this legacy, empowering our members to share their unique stories and experiences through this innovative geospatial tool."

Esri designed StoryMaps to enable everyone with varying digital skills to create custom content without requiring cartography or web design experience. StoryMaps allows authors to

  • Build a story in one place. Make versatile stories of any length using your assets (text, photos, videos, audio, etc.) or leverage Unsplash for ready-to-use images.
  • Publish and share your story with any audience. Make a private journal, create a shareable unlisted link for family and friends, or publish on all popular social media platforms. Authors can also embed stories on websites and blogs.
  • Add custom interactive maps. Bring readers along your journey by adding a map with graphics and pop-ups or create a thematic map to visualize trends.
  • Incorporate engaging features. Display content in different ways using flexible components including a timeline, image gallery, swipe, and quotes. All content can be organized into collections that act like folders.
  • Customize the look. Choose from built-in themes or customize a design with a different font, color, and layout options.
  • Keep it current. Update and publish stories easily with new features and capabilities every two weeks. Future features will include geo-ready data from wearables to show off your latest outdoor activities.

A free basic plan is available with essential storytelling capabilities to ensure all storytellers have access at any time. When new users sign up, they have free access to Premium features with enhanced storytelling capabilities for the first 30 days. After, they can decide to purchase a monthly or annual Premium subscription to StoryMaps at $10 or $100, respectively, or downgrade to the free, basic storytelling option.

To explore StoryMaps, read stories , and get started, visit storymaps.com .

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .

Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, StoryMaps, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye